Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hina Mohammed"'
Autor:
Guillermo Garcia-Manero, Rayna K. Matsuno, Ali Mcbride, Adeola Y Makinde, Thomas D. Brown, Danny Idryo, Ronda Broome, Autumn Herriman, Kristiana Wilkinson, Sheetal Walters, Andrew Schrag, Hina Mohammed, Monika A. Izano, Sudipto Mukherjee
Publikováno v:
HemaSphere, Vol 7, p e20066a9 (2023)
Externí odkaz:
https://doaj.org/article/9bceb06cd56d4794a5b7e37324d5d685
Publikováno v:
PLoS ONE, Vol 17, Iss 3 (2022)
Background Predictive models could help clinicians identify risk factors that cause adverse events after total knee arthroplasty (TKA), allowing for appropriate preoperative preventive interventions and allocation of resources. Methods The National I
Externí odkaz:
https://doaj.org/article/ab212549f51a43da965c26d97752c7ef
Autor:
Rama Jayaraj, Madurantakam Royam Madhav, Sankaranarayanan Gomathi Nayagam, Ananya Kar, Shubhangi Sathyakumar, Hina Mohammed, Maria Smiti, Shanthi Sabarimurugan, Chellan Kumarasamy, T. Priyadharshini, K. M. Gothandam, N Ramesh, Ajay Gupta, Siddhartha Baxi, Suja Swamiappan, Sunil Krishnan
Publikováno v:
Cells, Vol 8, Iss 10, p 1250 (2019)
Awareness of breast cancer has been increasing due to early detection, but the advanced disease has limited treatment options. There has been growing evidence on the role of miRNAs involved in regulating the resistance in several cancers. We performe
Externí odkaz:
https://doaj.org/article/c124b54f949940c5b3b7947f3beb12a0
Publikováno v:
Journal of Racial and Ethnic Health Disparities.
The growing opioid epidemic in the USA has underlying racial disparities dimensions. Also, studies have shown that patients from minority racial groups are at higher risk of adverse events following major orthopedic surgery. The aim of our study was
Publikováno v:
Cancer Research. 83:6655-6655
Background. Clinical trials (CT) include patients (pts) satisfying eligibility criteria including normal organ function and low comorbidity. Real-world outcomes for pts with aNSCLC receiving ICIs in 2L were compared based on whether pts met CT eligib
Autor:
Hina Mohammed, Connor Sweetnam, Jeanna Wallenta Law, Liz Toland, Anna B. Berry, Thomas D. Brown, Chenan Zhang
Publikováno v:
Journal of Clinical Oncology. 40:e15575-e15575
e15575 Background: Molecular testing is essential in considering targeted therapies, particularly for the increasing number of metastatic colon cancer (mCC) patients (pts) diagnosed at younger ages who may present with more aggressive disease. This a